Potential benefits:

• You may learn about your blood chemistry, precise detail about your AAA, and the possiblity that metformin may limit the progression of your AAA.

Potential risks:

• Risk of pain or bruising from blood draw, minimal exposure to radiation from 2 CT scans, and side effects related to metformin.

BENEFITS & RISK FACTORS OF LIMIT STUDY

CONTACT US

Study Research Coordinator

Lori McDonnell

650-498-5521

lorimcd2@stanford.edu

Go to: https://vascular.stanford.edu
Click on "Research"
then "Clinical Trials"
The LIMIT Trial is the first trial on the page

Stanford MEDICINE | Vascular Surgery

LIMITING AAA WITH METFORMIN:

THE LIMIT TRIAL

WHAT YOU NEED TO KNOW ABOUT THIS RESEARCH STUDY

PATIENT INFORMATION BROCHURE

LIMIT Research Study

You may be eligible if:

1) You have a diagnosis of AAA with a maximum of (or no larger than) 4.9 cm for males/4.5 cm for females
2) have not previous had surgical repair for AAA,
3) are non-diabetic,
4) are not taking any diabetic medication, including metformin

Why is this study being conducted?

This study is being conducted to determine whether treatment with metformin will significantly reduce enlargement of existing AAAs over two years in non-diabetic participants.

What happens if I qualify?

If you qualify, then you will be assigned by chance either to metformin or placebo.

Is my participation voluntary?

Yes, participation is completely voluntary. You can also decide to participate now, but withdraw your consent later and stop being in the study at any time.

How much time will the study take?

Two years (24 months)

Who is the primary study sponsor?

The National Institutes of Health. The Principal Investigators are Drs. Ronald Dalman, Kenneth Mahaffey, and Ying Lu.

TIME AND TRAVEL COMMITMENTS FOR LIMIT

There are 5 study contacts:

Baseline visit: Baseline blood and urine tests, CT scan, and questionnaires. Randomize to one of the 2 groups and receive study drug.

Three follow contacts (6, 12 & 18 months): Three follow-up contacts (6, 12 & 18 months): Blood tests, complete questionnaires, receive study drug.

Study completion visit (24 months): Final blood tests, CT scan, questionnaires and return remaining study drug.

Study visits may be conducted at Stanford or Emeryville, or by phone with local blood tests and recent CT scans completed elsewhere.